Skip to content

High Frequency Percussive Ventilation in COVID-19 Patients

High Frequency Percussive Ventilation in COVID-19 Patients Receiving Oxygen Through High-flow Nasal Cannula

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05358184
Enrollment
15
Registered
2022-05-03
Start date
2022-05-15
Completion date
2022-06-30
Last updated
2022-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure, COVID-19

Brief summary

High frequency percussive ventilation (HFPV) is used in patients with underlying pulmonary atelectasis, excessive airway secretions, and respiratory failure. HFPV is a non-continuous form of high-frequency ventilation delivered by a pneumatic device that provides small bursts of sub-physiological tidal breaths at a frequency of 60-600 cycles/minute superimposed on a patient's breathing cycle. The high-frequency breaths create shear forces causing dislodgement of the airway secretions. Furthermore, the HFPV breath cycle has an asymmetrical flow pattern characterized by larger expiratory flow rates, which may propel the airway secretions towards the central airway. In addition, the applied positive pressure recruits the lung units, resulting in a more homogeneous distribution of ventilation and improved gas exchange. In acute care and critical care settings, HFPV intervention is used in a range of patients, from spontaneously breathing patients to those receiving invasive mechanical ventilation where HFPV breaths can be superimposed on a patient's breathing cycle or superimposed on breaths delivered by a mechanical ventilator. The most common indications for HFPV use are reported as removal of excessive bronchial secretions, improving gas exchange, and recruitment of atelectatic lung segments. This study aims to assess the lung physiological response to HFPV in terms of aeration and ventilation distribution in patients with acute respiratory failure due to SARS-CoV-2 infection and requiring high flow oxygen therapy through nasal cannula

Interventions

High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz

Sponsors

University Magna Graecia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* acute respiratory failure with a nasal swab positive for SARS-CoV-2 * need for high-flow oxygen through nasal cannula

Exclusion criteria

* life threatening cardiac arrythmia * pneumothorax * acute spinal injury * chest trauma * hemodynamic instability * chest or abdominal surgery in the previous 7 days * pregnancy * enrollment in other study protocols

Design outcomes

Primary

MeasureTime frameDescription
Lung aeration5 minutes after the end of HFPV applicationTo evaluate if the application of High Frequency Percussive Ventilation (HFPV) will modify the lung aeration (as assessed by the end-expiratory lung impedance through EIT), as compared to baseline before the treatment

Secondary

MeasureTime frameDescription
Gas exchange5 minutes after the end of HFPV applicationTo evaluate if the application of High Frequency Percussive Ventilation (HFPV) will modify Arterial Blood Gases, as compared to baseline before the treatment

Contacts

Primary ContactFederico Longhini, MD
longhini.federico@gmail.com+393475395967

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026